S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

AVITA Medical (RCEL) Stock Price, News & Analysis

$16.03
-0.47 (-2.85%)
(As of 03/28/2024 ET)
Today's Range
$15.82
$16.65
50-Day Range
$13.91
$18.31
52-Week Range
$9.16
$21.70
Volume
126,171 shs
Average Volume
167,014 shs
Market Capitalization
$412.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.80

AVITA Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.4% Upside
$27.80 Price Target
Short Interest
Healthy
2.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.15) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

685th out of 938 stocks

Surgical & Medical Instruments Industry

69th out of 94 stocks

RCEL stock logo

About AVITA Medical Stock (NASDAQ:RCEL)

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

RCEL Stock Price History

RCEL Stock News Headlines

RCEL Oct 2024 17.500 put
RCEL Apr 2024 22.500 put
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
BRIEF-Seatrium Limited Says FY Revenue S$7.3 Bln
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Q4 2023 Earnings Preview
RCEL Mar 2024 15.000 call
AVITA Medical: Q3 Earnings Insights
See More Headlines
Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:RCEL
Fax
N/A
Employees
207
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$27.80
High Stock Price Target
$40.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+73.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-35,380,000.00
Pretax Margin
-70.43%

Debt

Sales & Book Value

Annual Sales
$50.14 million
Book Value
$1.92 per share

Miscellaneous

Free Float
25,203,000
Market Cap
$412.13 million
Optionable
Optionable
Beta
1.39

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. James M. Corbett (Age 66)
    CEO, President & Executive Director
    Comp: $1.16M
  • Mr. David O'Toole (Age 65)
    Chief Financial Officer
    Comp: $574.64k
  • Ms. Donna Shiroma (Age 61)
    General Counsel, Chief Compliance Officer & Secretary
    Comp: $688.6k
  • Mr. David Fencil
    Senior Vice President of Global Operations
  • Dr. Katie Bush Ph.D.
    Senior Vice President of Scientific & Medical Affairs
  • Ms. Jessica Ekeberg
    Investor Relations Executive
  • Ms. Debbie Garner
    Senior Vice President of Global Marketing & Strategy
  • Mr. Rob Hall
    Senior Vice President of Human Resources
  • Mr. Terry Bromley
    Senior Vice President of Global Sales
  • Dr. Niraj Doshi J.D.
    P.M.P., Ph.D., Senior Vice President of Product Development & Program Management

RCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell AVITA Medical stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCEL shares.
View RCEL analyst ratings
or view top-rated stocks.

What is AVITA Medical's stock price target for 2024?

5 brokers have issued twelve-month price targets for AVITA Medical's shares. Their RCEL share price targets range from $21.00 to $40.00. On average, they predict the company's share price to reach $27.80 in the next year. This suggests a possible upside of 73.4% from the stock's current price.
View analysts price targets for RCEL
or view top-rated stocks among Wall Street analysts.

How have RCEL shares performed in 2024?

AVITA Medical's stock was trading at $13.72 at the beginning of 2024. Since then, RCEL shares have increased by 16.8% and is now trading at $16.03.
View the best growth stocks for 2024 here
.

When is AVITA Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RCEL earnings forecast
.

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (NASDAQ:RCEL) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The firm earned $14.20 million during the quarter, compared to analyst estimates of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative trailing twelve-month return on equity of 54.80%.

What guidance has AVITA Medical issued on next quarter's earnings?

AVITA Medical issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.8 million-$15.6 million, compared to the consensus revenue estimate of $15.8 million.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO).

Who are AVITA Medical's major shareholders?

AVITA Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.45%), Vanguard Group Inc. (5.42%), Pura Vida Investments LLC (1.41%), Northern Trust Corp (0.88%), Dimensional Fund Advisors LP (0.37%) and 1492 Capital Management LLC (0.28%). Insiders that own company stock include David D O'toole, Donna Shiroma, James Corbett, Jeremy Curnock Cook, Michael S Perry, Michael S Perry and Suzanne Crowe.
View institutional ownership trends
.

How do I buy shares of AVITA Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCEL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners